Search for: "Novartis Pharma AG"
Results 81 - 100
of 124
Sorted by Relevance
|
Sort by Date
4 Mar 2009, 11:00 pm
(Spicy IP) Kenya enacts Biosafety Act 2/2009 regulating activities in GMOs, establishing National Biosafety Authority (Afro-IP) US: BIO meets the press: economic health of the biotech industry; follow-on biologics; patent reform (Patent Docs) (Patent Docs) (Intellectual Property Watch) US: Obama touts generic biologics to lower drug costs (Law360) US: Genentech announces victory in Cabilly re-examination (Patent Docs) US: Federal judge rejects Scruggs family’s bid to reconsider summary… [read post]
5 Apr 2023, 5:18 am
This then came before Arnold LJ in the Teva UK Limited and anor v Novartis AG [2022] EWCA Civ 1617 who agreed that no Arrow declaration should be made. [read post]
20 Dec 2018, 10:14 am
In the second decision, Novartis AG v. [read post]
1 Dec 2017, 11:35 am
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]
7 Mar 2022, 12:44 am
The machinations on the application of Article 3 to combination SPCs is just yet another example of the hazy ground that can open up between these two imperatives.Further reading28 June 2019: SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19)13 September 2019: Article 3(a) just keeps on giving: AG Opinion in SPC referrals C-650/17 and C-114/1817 May 2021: Does the Irish Court of Appeal in Merck v Clonmel part ways from the… [read post]
28 Nov 2017, 7:25 am
Dramatically Higher Price The newly approved drug, KymriahTM (tisagenlecleucel), manufactured by Novartis, brings hope to the 3,100 people under the age of 20 in the United States who are diagnosed each year with acute lymphoblastic leukemia. [read post]
3 May 2015, 10:33 pm
With this note, he provides further food for thought on patent law’s complexity, from Bilski to Teva v Leo Pharma, to the relation between patent law and economics. [read post]
29 Jan 2016, 3:58 am
If you want a reason to hate Novartis, look to Obamacare’s failure to address big pharma costs to buy its love and support for passage. [read post]
22 Sep 2016, 5:32 pm
An ageing population and the increase in chronic diseases are driving a dramatic market expansion. [read post]
23 Feb 2015, 2:55 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
26 Nov 2007, 7:44 pm
Xenon announced in September 2004 that it had an agreement with Novartis Pharma AG to commercialize related compounds. [read post]
23 Nov 2007, 9:00 am
You can separately subscribe to the IP Thinktank Global week in Review at [duncanbucknell.com]GlobalReputation and privacy in the online social media world: (IPWar's), McAfee typosquatting study results and implications: (IPWar's),Larry Lessig's comments on how creativity is being strangled by the law: (BLOG@IP::JUR)Two interesting papers on Creative Commons: (CreativeCommons)Friction and 'Warfighting': (IP Think Tank),More on the controversy at WIPO over Kamil Idris'… [read post]
23 Mar 2011, 1:30 pm
The drug is jointly developed by Genentech Inc., a member of the Roche group, under an agreement with Novartis Pharma AG. [read post]
17 Jan 2008, 10:00 pm
: (Against Monopoly),Structuring a decentralized world - Institute for Ethics and Emerging Technologies: The necessity of open biotechnology: (Patent Lens),A skeptical look at the Automated Content Access Protocol: (Ars Technica),5 practical things to incorporate in a corporate IP strategy: (IP ThinkTank), Legal models for online content enforcement: (OpenContentLawyer),Germany, Chinese copies and misdirected ‘strategy': (IP… [read post]
30 Apr 2019, 5:29 am
Jürgen Dressel (ex- Novartis Pharma AG) further commented that of course there is the further issue in Germany that invalidity proceedings cannot even be commenced whilst EPO opposition proceeding are ongoing. [read post]
28 Apr 2019, 8:20 am
In the Rituximab case (District Court of Munich, May 2017), the court said that the generic case law stipulating that the balance of interests in principle favors the originator cannot be applied to biosimilar situations and that a full assessment of the specific circumstances is required in each case.From the audience Jürgen Dressel (ex-Novartis Pharma AG, Basel) asked about the uptake of biosimilars and whether costs will decrease the more medicines… [read post]
2 Feb 2015, 2:20 am
Kleemans (Freshfields Bruckhaus Deringer LLP, Amsterdam) reports on the Hague Court of Appeal’s summary ruling in a case between Novartis AG and Sun Pharmaceutical Industries BV. [read post]
2 Mar 2015, 2:43 pm
Never too late 33 [week ending Sunday 15 February] –- Evoking Audrey Hepburn’s image is not OK in Italy | Reasonable royalty and moral prejudice: new reference to the CJEU | CoA for England and Wales on parallel importations in Speciality European Pharma Ltd v Doncaster Pharmaceuticals Group Ltd & Madaus GmbH | The Logic of Innovation: Intellectual Property, and What the User Found There and Tritton on Intellectual Property in Europe reviewed | Italian baked goods’… [read post]
16 Feb 2015, 1:44 am
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems & Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
30 Apr 2019, 7:22 am
Final panellist Jürgen Dressel (ex- Novartis Pharma AG) explained that, going back to basics, the SPC is meant to be a reward for R&D and there should be legal certainty and a harmonised situation for the international market. [read post]
